Go Pro

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,196.18 +10.31 (+0.87%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$1,196.51 +0.33 (+0.03%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company has demonstrated impressive financial performance, with a return on equity exceeding 100%, indicating effective management and profitability.
  • Eli Lilly and Co recently reported earnings per share significantly above analysts' expectations, showcasing strong operational efficiency and market demand for its products.
  • The current stock price is around $720, reflecting a robust market position and investor confidence in the company's future growth prospects.

Cons of Eli Lilly and Company

  • Despite strong earnings, the pharmaceutical industry is highly competitive, and Eli Lilly and Co faces pressure from generic alternatives and pricing regulations.
  • The company's reliance on a few key products for revenue could pose risks if market dynamics shift or if new competitors emerge.
  • While the dividend yield is currently low, it may not be sufficient to attract income-focused investors compared to other investment opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.13 trillion
P/E Ratio
42.49
Consensus Rating
Moderate Buy
Consensus Price Target
$1,283.64 (+7.3% Upside)
Volume
1.98 million shares
Average Volume
2.71 million shares
Today's Range
$1,187.50
$1,206.94
50-Day Range
$988.76
$1,233.32
52-Week Range
$623.78
$1,249.45
Dividend Yield
0.58%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$263.43 +4.16 (+1.60%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$263.30 -0.13 (-0.05%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The company recently reported earnings per share (EPS) of $2.90, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Johnson & Johnson has a robust return on equity of 32.86%, suggesting effective management and profitability, which can be attractive to investors looking for solid returns.
  • The firm announced a quarterly dividend of $1.34 per share, translating to an annualized dividend of $5.36 and a yield of 2.1%, appealing to income-focused investors.

Cons of Johnson & Johnson

  • There remains a legal overhang with ongoing talc-related cancer claims, which could pose risks to the company's reputation and financial stability.
  • The company's dividend payout ratio is currently at 62.11%, indicating a significant portion of earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.
  • Despite recent positive developments, the competitive landscape in the healthcare sector is intense, and Johnson & Johnson may face challenges in maintaining its market position.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$634.06 billion
P/E Ratio
30.52
Consensus Rating
Moderate Buy
Consensus Price Target
$265.30 (+0.7% Upside)
Volume
6.35 million shares
Average Volume
8.12 million shares
Today's Range
$259.61
$263.71
50-Day Range
$223.00
$267.35
52-Week Range
$164.23
$269.43
Dividend Yield
2.07%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$259.10 +2.18 (+0.85%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$258.78 -0.32 (-0.12%)
As of 07/24/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $229.80, which is near its 50-day moving average, indicating potential stability in the short term.
  • AbbVie recently reported strong quarterly earnings, with earnings per share surpassing analysts' expectations, showcasing the company's robust financial performance.
  • The company has a solid revenue growth of 12.4% compared to the same quarter last year, indicating a positive trend in its business operations.

Cons of AbbVie

  • AbbVie has a negative return on equity, which may raise concerns about its ability to generate profit from shareholders' investments.
  • The company's high price-to-earnings ratio suggests that the stock may be overvalued, which could lead to price corrections in the future.
  • AbbVie faces potential revenue declines from its older products, particularly Humira, as newer therapies enter the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$458.24 billion
P/E Ratio
127.64
Consensus Rating
Moderate Buy
Consensus Price Target
$268.10 (+3.5% Upside)
Volume
4.19 million shares
Average Volume
8.36 million shares
Today's Range
$256.77
$260.22
50-Day Range
$209.57
$260.88
52-Week Range
$187.62
$261.64
Dividend Yield
2.67%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$420.40 -3.16 (-0.75%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$420.14 -0.25 (-0.06%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company reported strong earnings per share of $6.38 for the latest quarter, significantly exceeding analysts' expectations, indicating robust financial performance.
  • UnitedHealth Group has set ambitious guidance for fiscal year 2026, projecting earnings per share between 19.500 and 20.000, which suggests potential for growth and profitability.
  • The current stock price is around $720, reflecting investor confidence and a solid market position in the healthcare sector.

Cons of UnitedHealth Group

  • The net margin of 3.14% is relatively low for a healthcare company, which may raise concerns about profitability and operational efficiency.
  • Despite a slight year-over-year revenue increase of 0.4%, the growth rate may not be sufficient to meet the high expectations set by analysts, potentially leading to volatility in stock performance.
  • The dividend payout ratio is currently at 59.72%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$382.09 billion
P/E Ratio
27.05
Consensus Rating
Moderate Buy
Consensus Price Target
$455.92 (+8.5% Upside)
Volume
3.75 million shares
Average Volume
5.82 million shares
Today's Range
$418.92
$429.00
50-Day Range
$377.48
$436.19
52-Week Range
$234.60
$461.62
Dividend Yield
2.19%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$131.06 +0.58 (+0.44%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$130.90 -0.16 (-0.12%)
As of 07/24/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has demonstrated strong financial performance, with a net margin indicating effective cost management and profitability.
  • The company has a robust return on equity, showcasing its ability to generate profits from shareholders' investments.
  • Merck's recent quarterly revenue exceeded analyst expectations, reflecting strong market demand for its products.

Cons of Merck & Co., Inc.

  • The company's high dividend payout ratio suggests that a significant portion of earnings is distributed to shareholders, which may limit funds available for reinvestment in growth opportunities.
  • Merck faces intense competition in the biopharmaceutical sector, which could impact its market share and pricing power.
  • Regulatory challenges and potential delays in product approvals can pose risks to Merck's growth trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$323.72 billion
P/E Ratio
36.92
Consensus Rating
Moderate Buy
Consensus Price Target
$133.94 (+2.2% Upside)
Volume
6.15 million shares
Average Volume
9.20 million shares
Today's Range
$130.24
$131.71
50-Day Range
$112.63
$131.06
52-Week Range
$76.66
$131.74
Dividend Yield
2.59%
Novartis stock logo

6. Novartis NYSE:NVS

$154.84 -1.30 (-0.83%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$154.38 -0.46 (-0.30%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The company has a strong return on equity, indicating effective management and profitability, which can be attractive for investors looking for solid financial performance.
  • Recent revenue figures show that Novartis AG exceeded analyst estimates, suggesting robust operational performance and potential for future growth.
  • Analysts have a generally positive outlook, with several upgrades to "overweight" ratings, indicating confidence in the company's future performance.

Cons of Novartis

  • The company reported earnings per share that missed analysts' expectations, which could raise concerns about its short-term profitability.
  • Quarterly revenue showed a slight decline year-over-year, indicating potential challenges in maintaining growth momentum.
  • Some analysts have downgraded their ratings, reflecting a cautious outlook on the stock's performance in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$295.78 billion
P/E Ratio
23.35
Consensus Rating
Hold
Consensus Price Target
$141.20 (-8.8% Downside)
Volume
1.83 million shares
Average Volume
1.84 million shares
Today's Range
$154.44
$156.38
50-Day Range
$143.27
$159.82
52-Week Range
$112.34
$170.46
Dividend Yield
1.99%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$48.76 +0.58 (+1.20%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$48.80 +0.04 (+0.07%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $46, which is significantly lower than its 52-week high, indicating potential for growth.
  • Recent approvals for the oral Wegovy pill for weight management in the EU enhance Novo Nordisk's competitive position in the obesity treatment market.
  • Positive developments in India, where Wegovy has been approved for treating metabolic dysfunction-associated steatohepatitis, expand the market for Novo Nordisk's products.

Cons of Novo Nordisk A/S

  • The stock has a relatively high price-to-earnings ratio, which may suggest that it is overvalued compared to its earnings potential.
  • Recent ratings from analysts have been mixed, with several downgrades to "hold," indicating uncertainty about future performance.
  • The company has a quick ratio below 1, suggesting potential liquidity issues, which could impact its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$217.76 billion
P/E Ratio
11.45
Consensus Rating
Hold
Consensus Price Target
$65.56 (+34.5% Upside)
Volume
10.80 million shares
Average Volume
9.00 million shares
Today's Range
$48.71
$49.52
50-Day Range
$41.05
$51.50
52-Week Range
$35.12
$71.79
Dividend Yield
3.58%
Thermo Fisher Scientific stock logo

8. Thermo Fisher Scientific NYSE:TMO

$567.34 -4.98 (-0.87%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$568.82 +1.48 (+0.26%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company has shown a solid revenue growth of 6.2% compared to the same quarter last year, indicating strong operational performance.
  • Thermo Fisher Scientific Inc. has set its FY 2026 guidance at an earnings per share (EPS) range of 24.640-25.120, suggesting positive future profitability expectations.
  • Analysts have a consensus price target of around $602.14, with a majority rating the stock as a "Moderate Buy," which may indicate potential for price appreciation.

Cons of Thermo Fisher Scientific

  • Despite the revenue growth, the stock has seen fluctuations, and the current price may not reflect its long-term value, leading to potential volatility.
  • The dividend payout ratio is relatively low at 10.34%, which may indicate that the company is reinvesting a significant portion of its earnings rather than returning them to shareholders.
  • Recent insider selling, including a COO selling 400 shares, could raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$211.18 billion
P/E Ratio
30.52
Consensus Rating
Moderate Buy
Consensus Price Target
$613.05 (+8.1% Upside)
Volume
2.94 million shares
Average Volume
2.17 million shares
Today's Range
$555.91
$574.00
50-Day Range
$442.16
$573.44
52-Week Range
$435.27
$643.99
Dividend Yield
0.33%
Amgen stock logo

9. Amgen NASDAQ:AMGN

$376.04 +4.54 (+1.22%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$374.50 -1.54 (-0.41%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has set its FY 2026 guidance for earnings per share (EPS) between 21.700 and 23.100, indicating strong future profitability potential.
  • Analysts expect Amgen Inc. to post an EPS of 22.31 for the current fiscal year, suggesting solid earnings performance that could attract investors.
  • The company's quarterly revenue has increased by 5.8% year-over-year, reflecting growth in its business operations and market demand for its products.

Cons of Amgen

  • Some analysts have downgraded their target prices for Amgen Inc., with Morgan Stanley reducing theirs from $340.00 to $333.00, which may indicate concerns about the stock's short-term performance.
  • Insider activity shows that a senior vice president sold a significant number of shares, which could signal a lack of confidence in the company's near-term prospects.
  • With a mix of ratings, including two "Sell" ratings among the analyst community, there may be differing opinions on the stock's future performance, leading to uncertainty for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$202.95 billion
P/E Ratio
26.17
Consensus Rating
Hold
Consensus Price Target
$356.62 (-5.2% Downside)
Volume
2.49 million shares
Average Volume
2.16 million shares
Today's Range
$372.16
$379.41
50-Day Range
$324.39
$376.04
52-Week Range
$269.77
$391.29
Dividend Yield
2.68%
Abbott Laboratories stock logo

10. Abbott Laboratories NYSE:ABT

$103.13 +2.38 (+2.36%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$103.12 0.00 (0.00%)
As of 07/24/2026 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The company has demonstrated strong revenue growth, with a year-over-year increase of 13.0%, indicating robust demand for its products and services.
  • Abbott Laboratories has set a positive earnings per share (EPS) guidance for Q3 2026, ranging from 1.380 to 1.460, which suggests potential profitability and investor confidence.
  • The current stock price is around $118.61, which is considered attractive given the company's strong market position and growth prospects.

Cons of Abbott Laboratories

  • Several analysts have recently lowered their price targets for Abbott Laboratories, indicating potential concerns about future growth and market conditions.
  • The company's payout ratio is currently at 70.59%, which may raise concerns about sustainability in dividend payments if earnings do not continue to grow.
  • There is a competitive landscape in the healthcare sector, which could impact Abbott Laboratories' market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$179.51 billion
P/E Ratio
33.38
Consensus Rating
Moderate Buy
Consensus Price Target
$118.61 (+15.0% Upside)
Volume
10.37 million shares
Average Volume
12.59 million shares
Today's Range
$101.50
$104.18
50-Day Range
$85.36
$103.13
52-Week Range
$81.97
$137.49
Dividend Yield
2.45%
Gilead Sciences stock logo

11. Gilead Sciences NASDAQ:GILD

$129.31 -1.55 (-1.18%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$130.46 +1.15 (+0.89%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $130, which is significantly lower than its 52-week high of $157.29, potentially offering a buying opportunity for investors looking for value.
  • Gilead Sciences, Inc. reported a strong earnings per share (EPS) of $2.03 for the latest quarter, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid net margin of approximately 31%, showcasing its ability to convert revenue into profit effectively.

Cons of Gilead Sciences

  • Analysts forecast a negative EPS of -0.77 for the current fiscal year, which could indicate potential challenges in maintaining profitability.
  • The company's debt-to-equity ratio of 0.89 suggests a relatively high level of debt compared to equity, which may pose risks in times of economic downturns.
  • Recent price target adjustments by analysts, with some lowering their expectations, may reflect concerns about the company's future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$160.55 billion
P/E Ratio
17.62
Consensus Rating
Moderate Buy
Consensus Price Target
$158.33 (+22.4% Upside)
Volume
5.53 million shares
Average Volume
7.12 million shares
Today's Range
$129.04
$131.65
50-Day Range
$121.48
$136.36
52-Week Range
$108.46
$157.29
Dividend Yield
2.54%
Pfizer stock logo

12. Pfizer NYSE:PFE

$24.52 -0.49 (-1.94%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$24.54 +0.01 (+0.04%)
As of 07/24/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. has demonstrated strong financial performance, with a recent quarterly revenue exceeding expectations, indicating robust demand for its products.
  • The company has a solid return on equity, showcasing effective management and profitability, which can be attractive to investors looking for stable returns.
  • Pfizer Inc. recently announced a quarterly dividend, reflecting its commitment to returning value to shareholders, with an annualized dividend yield of approximately 6.8%.

Cons of Pfizer

  • The company's payout ratio is notably high at 131.30%, which may raise concerns about sustainability in dividend payments if earnings do not grow as expected.
  • Pfizer Inc. has a relatively low quick ratio, indicating potential liquidity issues that could affect its ability to meet short-term obligations.
  • Despite recent revenue growth, the earnings per share have shown a decline compared to the same period last year, which could signal challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.86 billion
P/E Ratio
18.72
Consensus Rating
Hold
Consensus Price Target
$28.50 (+16.2% Upside)
Volume
28.88 million shares
Average Volume
41.06 million shares
Today's Range
$24.51
$24.75
50-Day Range
$23.64
$26.24
52-Week Range
$23.11
$28.75
Dividend Yield
7.01%
CVS Health stock logo

13. CVS Health NYSE:CVS

$107.64 +0.75 (+0.70%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$107.96 +0.32 (+0.30%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported earnings per share of $2.57, significantly exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company has shown a year-over-year revenue increase of 6.2%, reflecting its ability to grow and adapt in a competitive market.
  • Analysts have a positive outlook, with a consensus rating of "Moderate Buy" and an average target price suggesting potential for stock appreciation.

Cons of CVS Health

  • The company's net margin is relatively low at 0.72%, which may raise concerns about profitability and operational efficiency.
  • CVS Health Co. has a high dividend payout ratio of 117.18%, indicating that it pays out more in dividends than it earns, which could be unsustainable in the long run.
  • Despite positive earnings, the stock market can be volatile, and external economic factors may impact CVS Health Co.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$137.47 billion
P/E Ratio
47.42
Consensus Rating
Moderate Buy
Consensus Price Target
$105.67 (-1.8% Downside)
Volume
5.37 million shares
Average Volume
7.12 million shares
Today's Range
$106.91
$108.39
50-Day Range
$89.70
$110.40
52-Week Range
$58.99
$110.68
Dividend Yield
2.47%
Danaher stock logo

14. Danaher NYSE:DHR

$191.87 -0.63 (-0.33%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$191.25 -0.62 (-0.32%)
As of 07/24/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. reported earnings per share of $2.06 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company has a solid net margin of nearly 15%, suggesting efficient management and profitability, which can be attractive to investors looking for stable returns.
  • Danaher Co. has shown a year-over-year revenue increase of approximately 3.7%, reflecting its ability to grow even in competitive markets.

Cons of Danaher

  • The company's revenue for the latest quarter was slightly below analysts' expectations, which may raise concerns about its ability to meet future growth targets.
  • Recent downgrades from analysts, including a shift from "outperform" to "peer perform," could indicate a lack of confidence in the stock's short-term performance.
  • Danaher Co. has a relatively low return on equity of around 10.91%, which may suggest that the company is not utilizing its equity as effectively as some competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$134.62 billion
P/E Ratio
34.08
Consensus Rating
Moderate Buy
Consensus Price Target
$228.91 (+19.3% Upside)
Volume
6.85 million shares
Average Volume
5.80 million shares
Today's Range
$190.00
$194.80
50-Day Range
$164.08
$204.93
52-Week Range
$160.93
$242.80
Dividend Yield
0.84%
Bristol Myers Squibb stock logo

15. Bristol Myers Squibb NYSE:BMY

$62.05 +0.54 (+0.87%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$62.03 -0.02 (-0.03%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $57, which is significantly below its 12-month high, indicating potential for price appreciation.
  • Bristol-Myers Squibb has a strong market capitalization of approximately $124 billion, suggesting stability and investor confidence in the company.
  • The company reported a quarterly earnings per share (EPS) of $1.58, exceeding analysts' expectations, which reflects strong financial performance.

Cons of Bristol Myers Squibb

  • The company has a relatively high debt-to-equity ratio of 2.10, which may indicate financial risk and reliance on debt financing.
  • Recent quarterly revenue growth was only 2.6% compared to the same period last year, suggesting slower growth momentum.
  • Analysts have mixed ratings on the stock, with several firms issuing "neutral" ratings, indicating uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.79 billion
P/E Ratio
17.43
Consensus Rating
Hold
Consensus Price Target
$61.25 (-1.3% Downside)
Volume
12.07 million shares
Average Volume
10.40 million shares
Today's Range
$61.60
$62.82
50-Day Range
$54.10
$62.05
52-Week Range
$42.52
$62.89
Dividend Yield
4.06%
Stryker stock logo

16. Stryker NYSE:SYK

$330.69 +11.72 (+3.68%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$330.00 -0.69 (-0.21%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company has shown a steady revenue growth of 2.6% year-over-year, indicating a positive trend in its financial performance.
  • Stryker Co. has set its earnings per share (EPS) guidance for FY 2026 between 14.900 and 15.100, suggesting strong future profitability potential.
  • The current stock price is around $306, which may present a buying opportunity for investors looking for growth in the medical technology sector.

Cons of Stryker

  • Recent insider selling activity, including significant sales by executives, may raise concerns about the company's short-term outlook and insider confidence.
  • The dividend payout ratio is currently at 40.74%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Analysts predict an EPS of 14.98 for the current fiscal year, which is slightly below the company's own guidance, indicating potential challenges in meeting expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.60 billion
P/E Ratio
38.27
Consensus Rating
Moderate Buy
Consensus Price Target
$392.52 (+18.7% Upside)
Volume
2.37 million shares
Average Volume
2.50 million shares
Today's Range
$324.02
$330.81
50-Day Range
$293.36
$332.31
52-Week Range
$281.00
$404.14
Dividend Yield
1.07%
Vertex Pharmaceuticals stock logo

17. Vertex Pharmaceuticals NASDAQ:VRTX

$477.36 +4.27 (+0.90%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$477.66 +0.31 (+0.06%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported strong quarterly earnings, with earnings per share exceeding analysts' expectations, indicating robust financial performance.
  • Vertex Pharmaceuticals Incorporated has a high net margin, suggesting efficient management and profitability, which can be attractive to investors looking for financially sound companies.
  • The stock price has shown resilience, with a current price around $464, reflecting investor confidence and potential for growth.

Cons of Vertex Pharmaceuticals

  • Despite recent successes, the biotechnology sector can be volatile, and Vertex Pharmaceuticals Incorporated may face challenges from competitors or regulatory hurdles.
  • Insider selling activity has been noted, which could signal a lack of confidence among executives regarding the company's future performance.
  • The stock has experienced fluctuations, with a 1-year high and low indicating potential instability in its market performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.16 billion
P/E Ratio
28.31
Consensus Rating
Moderate Buy
Consensus Price Target
$559.61 (+17.2% Upside)
Volume
1.25 million shares
Average Volume
1.83 million shares
Today's Range
$472.58
$484.00
50-Day Range
$425.09
$529.59
52-Week Range
$362.50
$533.67
Dividend Yield
N/A
Intuitive Surgical stock logo

18. Intuitive Surgical NASDAQ:ISRG

$337.50 +5.48 (+1.65%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$337.19 -0.31 (-0.09%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The company is a leader in robotic-assisted surgical systems, particularly known for its latest da Vinci surgical systems, which enhance precision and control in minimally invasive surgeries.
  • Recent earnings projections indicate that Intuitive Surgical, Inc. is expected to post earnings per share of 8.61 for the current fiscal year, suggesting strong financial performance.
  • The current stock price is around $720, reflecting a robust market position and investor confidence in the company's growth potential.

Cons of Intuitive Surgical

  • Insider selling has been observed, with executives recently selling shares, which may indicate a lack of confidence in the company's short-term performance.
  • Despite strong earnings projections, market volatility can impact stock performance, and the healthcare sector can be particularly sensitive to regulatory changes.
  • Competition in the medical technology field is increasing, with other companies developing similar robotic surgical systems, which could affect market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.23 billion
P/E Ratio
38.66
Consensus Rating
Moderate Buy
Consensus Price Target
$523.46 (+55.1% Upside)
Volume
3.44 million shares
Average Volume
3.70 million shares
Today's Range
$332.15
$341.83
50-Day Range
$332.02
$449.03
52-Week Range
$328.57
$603.88
Dividend Yield
N/A
Medtronic stock logo

19. Medtronic NYSE:MDT

$83.12 +1.11 (+1.36%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$83.25 +0.13 (+0.16%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc has a strong market presence as one of the largest medical-device manufacturers, which positions it well for continued growth in the healthcare sector.
  • The company has received a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for stock appreciation.
  • Recent price targets from analysts suggest an average price target of around $98.21, which may indicate potential upside from the current stock price.

Cons of Medtronic

  • Company insiders own only 0.26% of the stock, which may indicate a lack of confidence from those closest to the company.
  • Recent price target reductions by analysts, such as a drop from $112.00 to $97.00, may signal concerns about the company's short-term performance.
  • Medtronic plc faces significant competition in the medical technology space, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$106.51 billion
P/E Ratio
22.28
Consensus Rating
Moderate Buy
Consensus Price Target
$98.21 (+18.1% Upside)
Volume
4.34 million shares
Average Volume
7.54 million shares
Today's Range
$82.41
$83.60
50-Day Range
$73.72
$83.78
52-Week Range
$73.31
$106.33
Dividend Yield
3.46%
Sanofi stock logo

20. Sanofi NASDAQ:SNY

$43.35 -0.01 (-0.02%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$43.35 +0.00 (+0.00%)
As of 07/24/2026 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $43.68, which is near its 1-year low, potentially offering a buying opportunity for value investors.
  • Sanofi has a strong market capitalization of approximately $108.66 billion, indicating a solid position in the pharmaceutical industry.
  • The company has a low debt-to-equity ratio of 0.20, suggesting financial stability and lower risk associated with debt obligations.

Cons of Sanofi

  • Despite recent upgrades, the average target price from analysts is around $49.50, indicating limited upside potential from the current stock price.
  • The company has a quick ratio of 0.73, which may raise concerns about its ability to meet short-term liabilities without selling inventory.
  • Sanofi's beta of 0.45 suggests lower volatility compared to the market, which may not appeal to investors seeking high-growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$105.10 billion
P/E Ratio
12.11
Consensus Rating
Hold
Consensus Price Target
$49.50 (+14.2% Upside)
Volume
3.07 million shares
Average Volume
3.21 million shares
Today's Range
$42.94
$43.49
50-Day Range
$41.33
$45.02
52-Week Range
$40.89
$52.68
Dividend Yield
4.07%
GSK stock logo

21. GSK NYSE:GSK

$51.38 +0.64 (+1.26%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$51.41 +0.03 (+0.06%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $40, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has a strong market capitalization of approximately $103.82 billion, indicating a solid position in the market and potential for growth.
  • The company has a dividend yield of 3.4%, providing a steady income stream for investors, which is attractive in a low-interest-rate environment.

Cons of GSK

  • The company has a debt-to-equity ratio of 0.80, which indicates a moderate level of debt that could pose risks if not managed properly.
  • GSK plc's current ratio of 0.79 suggests that the company may face challenges in meeting its short-term liabilities, which could impact liquidity.
  • Recent cuts to dividends may signal financial strain or a shift in company strategy, which could concern income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.87 billion
P/E Ratio
13.35
Consensus Rating
Hold
Consensus Price Target
$53.00 (+3.2% Upside)
Volume
5.86 million shares
Average Volume
3.77 million shares
Today's Range
$51.00
$51.57
50-Day Range
$49.06
$53.69
52-Week Range
$36.75
$61.69
Dividend Yield
3.49%
McKesson stock logo

22. McKesson NYSE:MCK

$840.76 +16.27 (+1.97%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$841.15 +0.39 (+0.05%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $771, which reflects a strong position in the market and potential for growth.
  • McKesson Co. reported a year-over-year revenue increase of 6.0%, indicating robust business performance and resilience in the healthcare sector.
  • The company has a solid earnings per share (EPS) of $11.69 for the latest quarter, surpassing analysts' expectations, which suggests strong profitability.

Cons of McKesson

  • McKesson Co. has a negative return on equity of 345.35%, which may raise concerns about the company's efficiency in generating profits from shareholders' equity.
  • The company’s revenue for the latest quarter fell short of analysts' expectations, which could indicate challenges in meeting market demands.
  • Despite a strong EPS, the net margin of 1.18% is relatively low, suggesting that the company may face pressure on profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$98.45 billion
P/E Ratio
21.85
Consensus Rating
Moderate Buy
Consensus Price Target
$962.67 (+14.5% Upside)
Volume
823,780 shares
Average Volume
992,959 shares
Today's Range
$827.48
$843.53
50-Day Range
$735.76
$842.14
52-Week Range
$637.00
$999.00
Dividend Yield
0.39%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$382.28 +5.78 (+1.54%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$381.42 -0.85 (-0.22%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company has shown a positive revenue growth of 4.3% year-over-year, indicating a strong demand for its healthcare services.
  • HCA Healthcare, Inc. has set its earnings per share (EPS) guidance for FY 2026 between 29.100 and 31.500, suggesting potential for profitability and growth.
  • The current stock price is around $392, which may present a buying opportunity for investors looking for value in the healthcare sector.

Cons of HCA Healthcare

  • The company reported a negative return on equity of 295.93%, which may raise concerns about its ability to generate profit from shareholders' investments.
  • HCA Healthcare, Inc. missed its earnings per share estimate in the last quarter, which could indicate potential challenges in meeting future financial expectations.
  • With a P/E ratio of 12.78, the stock may be perceived as overvalued compared to its earnings, suggesting that investors should be cautious.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.79 billion
P/E Ratio
12.80
Consensus Rating
Moderate Buy
Consensus Price Target
$483.45 (+26.5% Upside)
Volume
2.70 million shares
Average Volume
1.60 million shares
Today's Range
$376.48
$399.00
50-Day Range
$360.99
$423.06
52-Week Range
$330.00
$556.52
Dividend Yield
0.83%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$377.39 -1.92 (-0.51%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$378.20 +0.81 (+0.21%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$81.91 billion
P/E Ratio
16.77
Consensus Rating
Moderate Buy
Consensus Price Target
$440.90 (+16.8% Upside)
Volume
969,518 shares
Average Volume
1.67 million shares
Today's Range
$375.91
$382.79
50-Day Range
$372.20
$430.21
52-Week Range
$273.71
$436.24
Dividend Yield
1.82%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$290.06 +3.77 (+1.32%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$288.25 -1.81 (-0.62%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $281.72, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • The company reported a strong quarterly revenue increase of 4.6% year-over-year, indicating solid growth and demand for its services.
  • With a consensus rating of "Moderate Buy" from analysts, there is a positive outlook for the stock, suggesting potential for price appreciation.

Cons of Cigna Group

  • Recent downgrades from analysts, including a reduction in target prices, may indicate concerns about the company's future performance.
  • The stock has experienced fluctuations, with a twelve-month high of $315.47 and a low of $239.51, suggesting volatility that could deter risk-averse investors.
  • The company's debt-to-equity ratio of 0.69 indicates a moderate level of debt, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.60 billion
P/E Ratio
12.30
Consensus Rating
Moderate Buy
Consensus Price Target
$338.80 (+16.8% Upside)
Volume
1.08 million shares
Average Volume
1.62 million shares
Today's Range
$285.93
$290.57
50-Day Range
$271.03
$304.60
52-Week Range
$239.51
$315.47
Dividend Yield
2.15%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$656.01 +4.10 (+0.63%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$657.53 +1.52 (+0.23%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which reflects a strong performance in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. reported a significant earnings per share (EPS) of $9.47 for the latest quarter, exceeding analysts' expectations, indicating robust financial health.
  • The company achieved a revenue of $3.61 billion during the last quarter, showcasing a year-over-year growth of 19%, which suggests strong demand for its products.

Cons of Regeneron Pharmaceuticals

  • The price-to-earnings (P/E) ratio of 16.19 may suggest that the stock is fairly valued, limiting potential upside for investors looking for high-growth opportunities.
  • Despite strong earnings, the price-to-earnings-growth (PEG) ratio of 1.45 indicates that the stock may not be as undervalued as some investors might hope, which could deter value investors.
  • The company's beta of 0.24 suggests lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$69.35 billion
P/E Ratio
15.98
Consensus Rating
Moderate Buy
Consensus Price Target
$787.88 (+20.1% Upside)
Volume
708,359 shares
Average Volume
741,014 shares
Today's Range
$654.05
$667.50
50-Day Range
$600.66
$678.94
52-Week Range
$541.00
$821.11
Dividend Yield
0.57%
Boston Scientific stock logo

27. Boston Scientific NYSE:BSX

$44.26 +0.68 (+1.55%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$44.40 +0.14 (+0.31%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $55, which may be considered attractive compared to its 1-year high of $109.50, suggesting potential for growth.
  • Boston Scientific Co. recently reported a quarterly revenue increase of over 11%, indicating strong demand for its medical devices and a robust business model.
  • The company has a solid return on equity of 19.17%, reflecting effective management and profitability, which can be appealing to investors looking for efficient use of equity.

Cons of Boston Scientific

  • The stock has experienced significant volatility, with a 1-year low of $42.20, which may raise concerns about its stability and risk for investors.
  • The company has a debt-to-equity ratio of 0.42, which, while manageable, indicates that it is not entirely debt-free, potentially posing risks in a rising interest rate environment.
  • Despite recent revenue growth, the price-to-earnings ratio of 18.65 may suggest that the stock is relatively expensive compared to its earnings, which could deter value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$65.77 billion
P/E Ratio
18.52
Consensus Rating
Moderate Buy
Consensus Price Target
$79.84 (+80.4% Upside)
Volume
20.63 million shares
Average Volume
18.14 million shares
Today's Range
$43.72
$44.71
50-Day Range
$42.64
$57.71
52-Week Range
$42.20
$109.50
Dividend Yield
N/A
Cencora stock logo

28. Cencora NYSE:COR

$309.67 +4.61 (+1.51%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$308.70 -0.97 (-0.31%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The company has demonstrated strong financial performance with a return on equity of over 135%, indicating effective management and profitability relative to shareholder equity.
  • Cencora, Inc. has recently approved a significant stock repurchase program worth $2.00 billion, which suggests that the board believes the stock is undervalued and is committed to enhancing shareholder value.
  • The current stock price is around $270, which may present a buying opportunity for investors looking for growth in the healthcare sector.

Cons of Cencora

  • The net margin of 0.78% indicates that the company has relatively low profitability after expenses, which could be a concern for investors looking for high-margin businesses.
  • Despite the stock repurchase program, the overall market conditions and competition in the healthcare sector could impact Cencora, Inc.'s growth potential and stock performance.
  • With a projected earnings per share of 17.79 for the current fiscal year, any shortfall in meeting these expectations could negatively affect investor sentiment and stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.29 billion
P/E Ratio
23.75
Consensus Rating
Moderate Buy
Consensus Price Target
$367.75 (+18.8% Upside)
Volume
852,385 shares
Average Volume
1.49 million shares
Today's Range
$304.25
$310.30
50-Day Range
$262.15
$309.73
52-Week Range
$244.82
$377.54
Dividend Yield
0.77%
argenex stock logo

29. argenex NASDAQ:ARGX

$918.22 -6.38 (-0.69%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$918.84 +0.63 (+0.07%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company reported strong earnings per share (EPS) of $5.52 for the latest quarter, indicating robust profitability.
  • argenx SE has a high return on equity of 44.37%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
  • The current stock price is around $1,180, reflecting positive market sentiment and potential for further growth.

Cons of argenex

  • Despite strong earnings, the biotechnology sector can be highly volatile, and stock prices may fluctuate significantly based on market conditions and regulatory approvals.
  • There is a competitive landscape in the biotechnology field, which may impact argenx SE's market share and profitability.
  • While the company has a high return on equity, it also indicates a reliance on equity financing, which could dilute existing shareholders if new shares are issued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.44 billion
P/E Ratio
35.26
Consensus Rating
Moderate Buy
Consensus Price Target
$1,050.50 (+14.4% Upside)
Volume
324,071 shares
Average Volume
296,158 shares
Today's Range
$910.19
$935.88
50-Day Range
$776.26
$939.68
52-Week Range
$587.37
$953.58
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

30. Takeda Pharmaceutical NYSE:TAK

$17.23 +0.41 (+2.46%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$17.17 -0.06 (-0.37%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The company reported a solid earnings per share of $0.56 in its latest quarterly results, indicating strong profitability.
  • With a return on equity of 11.20%, Takeda Pharmaceutical Company Limited demonstrates effective management of shareholder equity, which can be attractive to investors.
  • The firm generated revenue of approximately $6.90 billion during the last quarter, showcasing its robust market presence and operational scale.

Cons of Takeda Pharmaceutical

  • The company has a net margin of only 4.31%, which may indicate challenges in maintaining profitability compared to competitors.
  • Analysts forecast a modest earnings per share of 1.12 for the current year, suggesting limited growth potential in the near term.
  • With 9.17% of the stock owned by hedge funds and institutional investors, there may be less room for retail investors to influence stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.24 billion
P/E Ratio
44.19
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
3.27 million shares
Average Volume
3.38 million shares
Today's Range
$17.22
$17.36
50-Day Range
$15.02
$17.23
52-Week Range
$12.99
$18.90
Dividend Yield
2.79%
Cardinal Health stock logo

31. Cardinal Health NYSE:CAH

$227.96 +1.98 (+0.88%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$225.50 -2.46 (-1.08%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $213, which is significantly lower than its 12-month high, indicating potential for growth.
  • Cardinal Health, Inc. recently reported earnings per share (EPS) of $3.17, exceeding analyst expectations, which reflects strong financial performance.
  • The company has increased its quarterly dividend to $0.5158 per share, demonstrating a commitment to returning value to shareholders.

Cons of Cardinal Health

  • The company has a negative return on equity of 92.61%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Cardinal Health, Inc. reported a net margin of only 0.62%, suggesting that its profitability is relatively low compared to its revenue.
  • Despite a recent increase in dividends, the dividend yield is only 0.9%, which may not be attractive for income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.41 billion
P/E Ratio
34.86
Consensus Rating
Moderate Buy
Consensus Price Target
$251.73 (+10.4% Upside)
Volume
1.47 million shares
Average Volume
2.26 million shares
Today's Range
$225.97
$228.97
50-Day Range
$194.96
$239.36
52-Week Range
$137.75
$243.21
Dividend Yield
0.91%
Edwards Lifesciences stock logo

32. Edwards Lifesciences NYSE:EW

$82.67 -1.15 (-1.37%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$82.56 -0.11 (-0.13%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported earnings per share (EPS) of $0.78 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Edwards Lifesciences Co. achieved a revenue of $1.65 billion for the quarter, surpassing forecasts, reflecting robust demand for its products and services.
  • With a return on equity of 15.19%, the company demonstrates effective management of shareholder equity, suggesting efficient use of capital to generate profits.

Cons of Edwards Lifesciences

  • Despite recent growth, the stock has faced fluctuations, which may indicate volatility and risk for investors looking for stable returns.
  • Some analysts have downgraded their ratings, suggesting that there may be concerns about future performance or market conditions affecting the company.
  • The company operates in a highly competitive medical technology sector, which could impact its market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.58 billion
P/E Ratio
47.51
Consensus Rating
Moderate Buy
Consensus Price Target
$99.55 (+20.4% Upside)
Volume
10.48 million shares
Average Volume
4.94 million shares
Today's Range
$82.53
$89.08
50-Day Range
$82.13
$95.17
52-Week Range
$72.30
$96.29
Dividend Yield
N/A
Humana stock logo

33. Humana NYSE:HUM

$388.56 -5.94 (-1.50%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$389.32 +0.76 (+0.20%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $400, reflecting a significant increase from its 52-week low, indicating strong market performance.
  • Humana Inc. reported a quarterly revenue of approximately $39.65 billion, surpassing analysts' expectations, which demonstrates robust business growth.
  • The company has shown a year-over-year revenue increase of 23.5%, suggesting strong demand for its health insurance products.

Cons of Humana

  • The company has a relatively low net margin of 0.82%, which may raise concerns about profitability compared to competitors.
  • Recent analyst ratings show a mix of opinions, with two analysts issuing a Sell rating, indicating some skepticism about future performance.
  • Humana Inc. has a high P/E ratio of 42.84, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.74 billion
P/E Ratio
41.56
Consensus Rating
Hold
Consensus Price Target
$327.17 (-15.8% Downside)
Volume
740,260 shares
Average Volume
1.28 million shares
Today's Range
$387.41
$399.61
50-Day Range
$302.69
$409.92
52-Week Range
$163.11
$428.88
Dividend Yield
0.91%
Becton, Dickinson and Company stock logo

34. Becton, Dickinson and Company NYSE:BDX

$156.26 +3.29 (+2.15%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$156.12 -0.14 (-0.09%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company has demonstrated a solid return on equity of over 15%, indicating effective management and profitability.
  • Recent revenue growth of approximately 5.2% year-over-year suggests a positive trend in sales and market demand for its medical products.
  • Becton, Dickinson and Company has set an earnings per share (EPS) guidance for FY 2026 between 12.520 and 12.720, which reflects confidence in future profitability.

Cons of Becton, Dickinson and Company

  • The company's dividend payout ratio is currently over 106%, which indicates that it is paying out more in dividends than it is earning, raising concerns about sustainability.
  • Insider selling activity has been noted, with executives selling shares, which could signal a lack of confidence in the company's short-term performance.
  • Analysts have mixed ratings on the stock, with several price target reductions, suggesting uncertainty about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.08 billion
P/E Ratio
39.56
Consensus Rating
Hold
Consensus Price Target
$180.29 (+15.4% Upside)
Volume
1.12 million shares
Average Volume
2.21 million shares
Today's Range
$153.32
$156.80
50-Day Range
$140.37
$159.85
52-Week Range
$127.59
$187.35
Dividend Yield
2.69%
Haleon stock logo

35. Haleon NYSE:HLN

$9.80 +0.09 (+0.88%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$9.80 0.00 (0.00%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $50, reflecting a strong market position in the consumer healthcare sector.
  • Haleon plc has seen significant institutional investment, indicating confidence from major financial players in its growth potential.
  • The company has a diverse product portfolio, including over-the-counter medicines and nutritional supplements, catering to a wide range of consumer health needs.

Cons of Haleon

  • Despite recent growth, Haleon plc's stock is still subject to market volatility, which can impact short-term investment returns.
  • The company operates in a highly competitive market, facing pressure from both established brands and new entrants.
  • Institutional ownership is currently at 6.67%, which may indicate limited interest from larger investors compared to other companies.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.08 billion
P/E Ratio
25.12
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
11.50 million shares
Average Volume
7.73 million shares
Today's Range
$9.73
$9.83
50-Day Range
$8.71
$10.12
52-Week Range
$8.65
$11.28
Dividend Yield
2.58%
IDEXX Laboratories stock logo

36. IDEXX Laboratories NASDAQ:IDXX

$544.32 +4.96 (+0.92%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$544.09 -0.23 (-0.04%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The company reported strong earnings per share (EPS) of $3.47 for the latest quarter, exceeding expectations, which indicates robust financial performance and potential for continued growth.
  • IDEXX Laboratories, Inc. has a high net margin of approximately 24.63%, suggesting efficient management and profitability, which can be attractive to investors looking for financially sound companies.
  • The current stock price is around $720, reflecting a solid market position and investor confidence in the company's future prospects.

Cons of IDEXX Laboratories

  • Recent price target reductions by analysts, such as UBS Group lowering their target from $730 to $640, may indicate concerns about the stock's short-term performance.
  • Despite strong earnings, the stock has faced downgrades from some analysts, which could signal a lack of confidence in the company's ability to maintain its growth trajectory.
  • The competitive landscape in the diagnostic products market is intense, which could pressure IDEXX Laboratories, Inc.'s market share and profitability in the future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.94 billion
P/E Ratio
40.08
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+38.0% Upside)
Volume
437,352 shares
Average Volume
648,163 shares
Today's Range
$535.85
$547.69
50-Day Range
$526.44
$578.89
52-Week Range
$518.55
$769.98
Dividend Yield
N/A
Revolution Medicines stock logo

37. Revolution Medicines NASDAQ:RVMD

$189.23 +0.48 (+0.25%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$189.88 +0.65 (+0.34%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$40.23 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$144.67 (-23.5% Downside)
Volume
1.29 million shares
Average Volume
2.57 million shares
Today's Range
$185.89
$190.50
50-Day Range
$144.19
$192.62
52-Week Range
$34.00
$193.82
Dividend Yield
N/A
Agilent Technologies stock logo

38. Agilent Technologies NYSE:A

$138.65 -1.09 (-0.78%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$138.35 -0.30 (-0.22%)
As of 07/24/2026 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The company recently reported earnings per share (EPS) of $1.49, exceeding expectations, which indicates strong financial performance and effective management.
  • Agilent Technologies, Inc. has a robust return on equity of over 24%, suggesting that it is efficiently generating profits from its equity investments.
  • The firm has shown a revenue increase of approximately 10% compared to the same quarter last year, reflecting growth in its market presence and product demand.

Cons of Agilent Technologies

  • The company's dividend payout ratio is currently at 20.48%, which, while sustainable, may limit the potential for future dividend increases.
  • Despite positive growth, the stock has faced target price reductions from analysts, indicating some uncertainty about its future performance.
  • With a consensus rating of "Moderate Buy," there may be a lack of overwhelming confidence among analysts, which could suggest caution for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.14 billion
P/E Ratio
27.84
Consensus Rating
Moderate Buy
Consensus Price Target
$159.35 (+14.9% Upside)
Volume
1.52 million shares
Average Volume
2.25 million shares
Today's Range
$138.02
$140.88
50-Day Range
$110.43
$139.68
52-Week Range
$108.35
$160.27
Dividend Yield
0.74%
Natera stock logo

39. Natera NASDAQ:NTRA

$261.99 -2.70 (-1.02%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$261.86 -0.13 (-0.05%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$37.52 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$267.83 (+2.2% Upside)
Volume
699,369 shares
Average Volume
1.28 million shares
Today's Range
$260.27
$266.87
50-Day Range
$192.54
$283.80
52-Week Range
$131.81
$288.04
Dividend Yield
N/A
Waters stock logo

40. Waters NYSE:WAT

$374.49 -7.92 (-2.07%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$374.20 -0.29 (-0.08%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$36.79 billion
P/E Ratio
47.59
Consensus Rating
Moderate Buy
Consensus Price Target
$401.60 (+7.2% Upside)
Volume
819,189 shares
Average Volume
857,624 shares
Today's Range
$372.51
$384.23
50-Day Range
$332.45
$384.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

41. Alnylam Pharmaceuticals NASDAQ:ALNY

$271.77 +3.03 (+1.13%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$270.93 -0.84 (-0.31%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The company recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health and operational efficiency.
  • Alnylam Pharmaceuticals, Inc. achieved a remarkable year-over-year revenue growth of nearly 100%, showcasing its ability to expand and capture market share effectively.
  • The stock has a high return on equity, suggesting that the company is proficient in generating profits from its equity investments, which can be attractive to investors looking for efficient management.

Cons of Alnylam Pharmaceuticals

  • Despite recent successes, the company has experienced insider selling, which can sometimes signal a lack of confidence from those closest to the business.
  • Alnylam Pharmaceuticals, Inc. operates in a highly competitive biopharmaceutical market, which can pose risks to its market position and profitability.
  • The stock has seen significant price fluctuations, which may indicate volatility and risk for investors who prefer stable investments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.28 billion
P/E Ratio
74.25
Consensus Rating
Moderate Buy
Consensus Price Target
$452.13 (+66.4% Upside)
Volume
1.15 million shares
Average Volume
1.50 million shares
Today's Range
$265.64
$275.58
50-Day Range
$266.99
$323.50
52-Week Range
$262.21
$495.55
Dividend Yield
N/A
BeOne Medicines stock logo

42. BeOne Medicines NASDAQ:ONC

$325.90 -0.87 (-0.27%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$328.44 +2.54 (+0.78%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$35.76 billion
P/E Ratio
72.91
Consensus Rating
Moderate Buy
Consensus Price Target
$394.00 (+20.9% Upside)
Volume
348,062 shares
Average Volume
377,706 shares
Today's Range
$324.92
$331.52
50-Day Range
$260.27
$326.77
52-Week Range
$253.95
$385.22
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

43. Teva Pharmaceutical Industries NYSE:TEVA

$30.78 -0.40 (-1.27%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$30.85 +0.07 (+0.21%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$35.43 billion
P/E Ratio
23.15
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+35.7% Upside)
Volume
3.13 million shares
Average Volume
4.53 million shares
Today's Range
$30.77
$31.86
50-Day Range
$30.19
$35.32
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
IQVIA stock logo

44. IQVIA NYSE:IQV

$208.22 +0.90 (+0.44%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$208.02 -0.21 (-0.10%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The company reported strong earnings of $2.90 per share, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • With a revenue of $4.15 billion for the quarter, surpassing estimates, IQVIA Holdings Inc. demonstrates solid growth potential in the medical research sector.
  • The company has a high return on equity of 30.50%, suggesting effective management and a strong ability to generate profits from shareholders' equity.

Cons of IQVIA

  • Despite strong earnings, the stock has received mixed ratings from analysts, with some downgrading their price targets, indicating potential volatility.
  • The company's net margin of 8.33% may be considered low compared to industry standards, which could raise concerns about profitability in competitive markets.
  • There is a consensus expectation of 11.57 EPS for the current fiscal year, which may not meet the growth expectations of more aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.72 billion
P/E Ratio
25.80
Consensus Rating
Moderate Buy
Consensus Price Target
$225.71 (+8.4% Upside)
Volume
1.09 million shares
Average Volume
1.17 million shares
Today's Range
$206.92
$209.99
50-Day Range
$161.94
$210.63
52-Week Range
$154.50
$247.04
Dividend Yield
N/A
Royalty Pharma stock logo

45. Royalty Pharma NASDAQ:RPRX

$58.83 -0.19 (-0.32%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$57.70 -1.13 (-1.92%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The company has demonstrated strong financial performance with a net margin of nearly 34%, indicating efficient management and profitability.
  • Royalty Pharma plc has a solid return on equity of over 29%, suggesting that it effectively generates profits from shareholders' investments.
  • The current stock price is around $54, which is within a range that has shown potential for growth, given its 52-week high of approximately $58.

Cons of Royalty Pharma

  • The company reported revenue of $630.58 million, which fell short of analyst expectations, indicating potential challenges in meeting market forecasts.
  • Royalty Pharma plc has a relatively high price-to-earnings ratio of around 39, which may suggest that the stock is overvalued compared to its earnings.
  • Insider selling activity has been noted, with executives selling significant shares, which could raise concerns about their confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.88 billion
P/E Ratio
40.02
Consensus Rating
Buy
Consensus Price Target
$56.57 (-3.8% Downside)
Volume
2.11 million shares
Average Volume
2.89 million shares
Today's Range
$58.51
$59.72
50-Day Range
$52.07
$59.02
52-Week Range
$34.08
$59.72
Dividend Yield
1.60%
Alcon stock logo

46. Alcon NYSE:ALC

$67.88 +0.67 (+1.00%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$67.90 +0.02 (+0.03%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $87.48, which reflects a strong market position and potential for growth.
  • Alcon Inc. has shown a month-to-month increase in shares shorted, indicating growing interest from investors, which can lead to increased stock demand.
  • The company has a relatively low short percentage of float, suggesting that most investors are optimistic about its future performance.

Cons of Alcon

  • The company has experienced a decline in its fifty-two week performance, which may raise concerns about its growth trajectory.
  • There has been a significant increase in shares shorted compared to the previous month, which could indicate that some investors are betting against the stock.
  • Alcon Inc. has a relatively high number of days to cover, suggesting that it may take longer for short sellers to cover their positions, which can lead to volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.59 billion
P/E Ratio
40.89
Consensus Rating
Moderate Buy
Consensus Price Target
$84.76 (+24.9% Upside)
Volume
1.26 million shares
Average Volume
2.06 million shares
Today's Range
$67.42
$68.36
50-Day Range
$64.05
$70.60
52-Week Range
$61.83
$91.86
Dividend Yield
N/A
Zoetis stock logo

47. Zoetis NYSE:ZTS

$75.32 +0.75 (+1.01%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$76.00 +0.68 (+0.90%)
As of 07/24/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has demonstrated strong financial performance, with a recent earnings per share (EPS) of $1.53, indicating solid profitability despite missing the consensus estimate slightly.
  • The company has a high return on equity of approximately 66.85%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
  • Zoetis Inc. has a robust net margin of around 27.80%, reflecting its efficiency in converting revenue into actual profit, which is attractive for potential investors.

Cons of Zoetis

  • The company recently missed revenue expectations, reporting $2.26 billion against a consensus estimate of $2.30 billion, which may raise concerns about future growth potential.
  • Analysts have downgraded their price targets for Zoetis Inc., with some reducing their estimates significantly, indicating a lack of confidence in short-term performance.
  • Despite a strong historical performance, the recent earnings miss could signal potential challenges in maintaining growth momentum in a competitive market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.59 billion
P/E Ratio
12.49
Consensus Rating
Hold
Consensus Price Target
$119.50 (+58.6% Upside)
Volume
5.09 million shares
Average Volume
6.09 million shares
Today's Range
$74.28
$76.06
50-Day Range
$71.88
$82.05
52-Week Range
$71.47
$160.48
Dividend Yield
2.81%
Centene stock logo

48. Centene NYSE:CNC

$63.35 -0.39 (-0.61%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$63.25 -0.10 (-0.16%)
As of 07/24/2026 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The company reported strong earnings per share of $3.37 for the latest quarter, significantly exceeding analysts' expectations, which indicates robust financial performance.
  • Centene Co. achieved a revenue of approximately $49.94 billion for the quarter, surpassing forecasts, showcasing its ability to grow and capture market share.
  • With a positive return on equity of 5.57%, Centene Co. demonstrates effective management of shareholder equity, which can be appealing to investors looking for efficient capital use.

Cons of Centene

  • Centene Co. has a negative net margin of 3.25%, indicating that the company is currently spending more than it earns, which could raise concerns about long-term profitability.
  • Despite recent growth, the company operates in a highly competitive healthcare market, which may pressure margins and limit future growth opportunities.
  • Institutional investors hold a significant 93.63% of the company's stock, which could lead to volatility if large stakeholders decide to sell their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.31 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$64.61 (+2.0% Upside)
Volume
2.81 million shares
Average Volume
4.10 million shares
Today's Range
$62.97
$64.60
50-Day Range
$57.19
$68.63
52-Week Range
$25.08
$69.36
Dividend Yield
N/A
Veeva Systems stock logo

49. Veeva Systems NYSE:VEEV

$186.06 +6.48 (+3.61%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$185.86 -0.20 (-0.11%)
As of 07/24/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The company reported earnings per share of $2.24 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Veeva Systems Inc. achieved a revenue of approximately $882.95 million during the quarter, reflecting a significant year-over-year increase of 16.3%, showcasing its expanding market presence.
  • The current stock price is around $190, which may present a favorable entry point for investors looking to capitalize on the company's growth trajectory.

Cons of Veeva Systems

  • Despite strong earnings, some analysts have downgraded their price targets, with BMO Capital Markets reducing their target from $220 to $175, which may signal concerns about future growth.
  • The company faces increasing competition in the cloud software sector for life sciences, which could impact its market share and profitability.
  • Insider selling activity has been noted, with a director selling shares, which could raise concerns about the company's future prospects from an insider's perspective.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.25 billion
P/E Ratio
33.17
Consensus Rating
Moderate Buy
Consensus Price Target
$247.08 (+32.8% Upside)
Volume
1.06 million shares
Average Volume
1.93 million shares
Today's Range
$182.00
$187.19
50-Day Range
$153.20
$197.74
52-Week Range
$148.05
$310.50
Dividend Yield
N/A
Biogen stock logo

50. Biogen NASDAQ:BIIB

$202.19 +1.57 (+0.78%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$201.20 -1.00 (-0.49%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. recently reported earnings per share of $3.57, significantly exceeding analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has set a fiscal year 2026 guidance of earnings per share between 14.250 and 15.250, suggesting confidence in its ongoing profitability and operational efficiency.
  • With a current stock price around $220, Biogen Inc. is viewed positively by analysts, with a consensus rating of "Moderate Buy" and a target price reflecting potential upside.

Cons of Biogen

  • Despite recent positive earnings, the company has faced challenges in maintaining consistent revenue growth, with only a 1.9% increase year-over-year.
  • Some analysts have issued mixed ratings, including a downgrade to "strong sell" from Zacks Research, indicating potential concerns about the stock's future performance.
  • Biogen Inc. operates in a highly competitive biotechnology sector, which can lead to volatility and uncertainty regarding its market share and product pipeline.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.85 billion
P/E Ratio
21.69
Consensus Rating
Moderate Buy
Consensus Price Target
$220.57 (+9.1% Upside)
Volume
596,261 shares
Average Volume
1.44 million shares
Today's Range
$200.04
$203.30
50-Day Range
$187.80
$216.63
52-Week Range
$124.56
$219.72
Dividend Yield
N/A